 Home > Medical News > Latest Medical News > Huabei Pharmaceutical's new rabies drug, omiltivizumab, has not been approved for large specifications

Huabei Pharmaceutical's new rabies drug, omiltivizumab, has not been approved for large specifications

 Last Update: 2021-09-05
 Source: Internet
 Author: User

Tags

heroin mechanism action

brilinta drug class

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Article source: Medical Rubik's Cube Info

On August 12, North China Pharmaceutical submitted a new class 1 recombinant human anti-rabies monoclonal antibody (ormutivimab) for the passive immunization of rabies virus-exposed patients.

Omotivirumab (rhRIG, NM57) is an independent innovation project of North China Pharmaceutical, and is listed as a major scientific and technological special product of the country’s “Major New Drug Creation”.

On June 28, 2007, North China Pharmaceutical submitted the first clinical trial application for this product (200 IU/bottle, 500 IU/bottle), and obtained the clinical trial approval on June 25, 2009

Huabei Pharmaceutical obtained the Phase III clinical trial approval issued by CFDA in July 2018

The conclusion of the trial reviewed by experts is that the post-exposure prevention of rhRIG combined with human rabies vaccine on people who are exposed to suspected rabies virus at level III reaches the primary efficacy and secondary efficacy endpoints, and the safety is good, reaching the target set by the protocol.

The passive immunization agents currently used for rabies virus post-exposure prevention in China are mainly anti-rabies serum (ERIG) and HRIG

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.